Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price objective lowered by Barclays from $18.00 to $13.00 in a report published on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other equities analysts have also recently commented on TNGX. Cantor Fitzgerald initiated coverage on shares of […]

Related Keywords

Piper Sandler , Barclays , Artal Group , Pricet Rowe Associates Inc , Vanguard Group Inc , Susquehanna Fundamental Investments , Securities Exchange Commission , Paloma Partners Management Co , Mva Investors Llc , Cantor Fitzgerald , Tango Therapeutics Inc , Tango Therapeutics , Free Report , Get Free Report , Mva Investors , Exchange Commission , Tango Therapeutics Daily ,